Share Icon Health Study Area: Cardiovascular Disease Chevron Icon Health Study Area: Genitourinary For Patients Health Study Area: Lung Cancer Page Icon Phone Icon For Caregivers Health Study Area: AutoImmune Disease Health Study Area: Melanoma Location Icon Print YouTube Icon For Parents Health Study Area: Lung Cancer Print Created with Sketch. Help Icon Green Check Icon Search Icon Instagram Created with sketchtool. Direction Arrow Icon Error Icon For Parents Health Study Area: Blood Cancer Help Icon Health Study Area: NASH Gender Both Bookmark Icon Health Study Area: Melanoma Created with Sketch. Glossary Print Health Study Area: Blood Cancer Health Study Area: Genitourinary Health Study Area: Gastrointestinal Cancer Mobile Menu Icon Created with Sketch. Health Study Area: Cardiovascular Disease Health Study Area: Women's Cancer Communities Map Icon Created with Sketch. For Caregivers Health Study Area: Fibrosis Health Study Area: AutoImmune Disease FAQs Health Study Area: Head and Neck Cancer Created with Sketch. For Clinicians Chevron Right Icon Gender Female Health Study Area: Breast Cancer Direction Arrow Icon Gender Both Right Arrow Icon LinkedIn Icon Green Check Icon Gender Male Health Study Area: Fibrosis For Patients Twitter Icon Email Icon Facebook Icon Health Study Area: Gastrointestinal Cancer Health Study Area: Head and Neck Cancer For Clinicians External Link Icon

Menü

Klinische Studien von BMS suchen
BMS-Symbol für "Studie, für die rekrutiert wird"

Recruiting

Studien-Nr. CA127-1070  |   NCT06352528

A Study to Assess the Drug Levels of Repotrectinib in Healthy Participants and Participants With Moderate and Severe Hepatic Impairment

Zusammenfassung

  • Phase 1
  • Symbol für männliches und weibliches Geschlecht
  • 18-75
    Altersgruppe
  • 3
    Standorte
  • BMS-Symbol für "Studie, für die rekrutiert wird"
    Recruiting

Überblick

The purpose of this study is to assess the drug levels of a single oral dose of repotrectinib in participants with moderate and severe HI, and in healthy matched control participants with normal hepatic function.

Nächstgelegenes Prüfzentrum

Wichtigste Einschlusskriterien

Inclusion Criteria: - Inclusion Criteria for all Participants (Group 1, Group 2, Group 3):. i) Adult female (as assigned at birth) not of childbearing potential or male (as assigned at birth) of any race or ethnicity. ii) Must have a body mass index between 18 and 40 kg/m2 (inclusive) and body weight ≥ 50 kg at the time of signing the ICF. - Inclusion Criteria for Participants with Moderate or Severe Hepatic Impairment (Group 1 and Group 2):. i) Participants have moderate or severe HI or cirrhosis due to chronic hepatic disease and/or prior alcohol use. ii) Participants have moderate (Group 1), or severe (Group 2) HI as defined by Child-Pugh score. - Inclusion Criteria for a Matched Healthy Participant (Group 3):. i) Participant must be free of any clinically significant disease that would interfere with the study evaluations. ii) Participant must have liver-related laboratory test results within the respective reference ranges or with clinically insignificant excursions therefrom as agreed by the investigator. iii) Participant must be in good health as determined by past medical history, physical examination, vital signs, ECG, and clinical laboratory safety tests. Clinical laboratory safety tests (eg, hematology, chemistry, and urinalysis) and 12-lead ECGs must be within normal limits or clinically acceptable as judged by the investigator. Exclusion Criteria: - Exclusion Criteria for all Participants (Group 1, Group 2, and Group 3):. i) Any major surgery within 4 weeks of the study intervention administration. ii) History of drug abuse within 1 year of study intervention administration. iii) History of alcohol abuse within 1 year of study intervention administration. iv) Participants who currently smoke, as well as those who have stopped smoking less than 6 months prior to dosing on Day 1. - Other protocol-defined Inclusion/Exclusion criteria apply.

Behandlungsmöglichkeiten

Studienarme

ZUGEWIESENE BEHANDLUNG

Studienarme

Experimental: Group 1: Moderate Hepatic Impairment

ZUGEWIESENE BEHANDLUNG
  • Drug: Repotrectinib

Studienarme

Experimental: Group 2: Severe Hepatic Impairment

ZUGEWIESENE BEHANDLUNG
  • Drug: Repotrectinib

Studienarme

Experimental: Group 3: Normal Hepatic Function

ZUGEWIESENE BEHANDLUNG
  • Drug: Repotrectinib
Prüfen Sie, ob eine der klinischen Studien für Sie infrage kommt
Kommt die Studie für Sie infrage
Beantworten Sie einige Fragen zu Ihrer Gesundheit, um festzustellen, ob diese Studie für Sie infrage kommt
Geeignete Studie
Wenn ihnen eine passende Studie angezeigt wird, klicken Sie auf die Studie, damit Sie die Liste der Prüfzentren angezeigt bekommen.
Wählen Sie einen Prüfzentrumsstandort aus
Wählen Sie einen Prüfzentrumsstandort aus, der für Sie günstig ist
Registrieren
Geben Sie Ihre Kontaktdaten ein, damit das Prüfzentrum mit Ihnen Kontakt aufnehmen kann.

Unterstützen Sie uns dabei, Ihre Nutzung der Website zu optimieren! Teilen Sie Ihr Feedback mit unserem Team bei BMS Clinical Trials, um die Nutzung der Webseite, Ihre Erfahrungen und die anderer zu verbessern. Vielen Dank!